drugset / Trial / NCT01913964
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.
Timeline
- Start
- 1997-10
- Primary completion
- 1997-10
- Completion
- 1997-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetylcarnitine | Small molecule | 2 g | — |
Indications
No indication recorded.